We propose to use the power and ease of C. elegans genetics in a core capacity to extend existing substance abuse research in new directions. We will use this genetically-tractable organism to pursue novel areas of study related to funded projects and to answer other questions not easily addressed in a mammalian system that are posed by ourselves and the large group of drug abuse researchers at this and neighboring institutions. The end goal of this core-provided research will be to better understand mechanisms of action of drugs of abuse, including identification and elaboration of genes and pathways that are important in drug effects, and to provide a biological system where alterations in nervous system function can be genetically controlled with ease to aid in drug development and drug selection. This core will allow investigators who would not otherwise make use of C. elegans in their own laboratories the opportunity to collaborate with scholars who have extensive experience with this organism and together pursue these novel lines of research investigation. There are three main areas of focus proposed by this C. elegans genetics core. 1) To use C. elegans genetics, pharmacology and a battery of phenotypic assays to understand the effects of alterations in specific genes, specific biological pathways or to better understand the effect of a drug with unclear mechanisms of action. This approach will link the action of drugs with well characterized biological pathways and neurotransmitter systems that can be dissected further using C. elegans genetics. 2) To use C. elegans to carry out reverse and forward genetic screens for genes that are important in mediating phenotypic effects of interest, such as drug-induced phenotypes, or phenotypes produced through alteration of a biological system related to substance abuse. This approach has the potential to identify genes not previously known to be involved with specific drug effects. 3) To use C. elegans to develop living bioassays to take advantage of whole organism drug effects and integration of to vivo biological systems. This approach will allow for refinement of drug development strategies using a whole animal system. These approaches will bring the innovation associated with this powerful genetic system to substance abuse research and generate significant novel findings that will allow researchers to better understand the genetic underpinnings of the mechanisms of action of drugs of abuse.

Public Health Relevance

C. elegans is a powerful genetic model system with a relatively simple nervous system that shares many conserved components with the human brain. Genetic approaches utilizing mutants and transgene techniques will be used to identify genes and biological processes that are important for the action of drugs of abuse and to allow for the development of drugs used to treat substance abuse.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1-EXL-T (02))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Virginia Commonwealth University
United States
Zip Code
Wiley, Jenny L; Walentiny, D Matthew; Wright Jr, M Jerry et al. (2014) Endocannabinoid contribution to ?9-tetrahydrocannabinol discrimination in rodents. Eur J Pharmacol 737:97-105
Schlosburg, Joel E; Kinsey, Steven G; Ignatowska-Jankowska, Bogna et al. (2014) Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout mice. J Pharmacol Exp Ther 350:196-204
Samano, Kimberly L; Poklis, Justin L; Lichtman, Aron H et al. (2014) Development of a high-performance liquid chromatography-tandem mass spectrometry method for the identification and quantification of CP-47,497, CP-47,497-C8 and JWH-250 in mouse brain. J Anal Toxicol 38:307-14
Suzuki, Joji; Poklis, Justin L; Poklis, Alphonse (2014) "My friend said it was good LSD": a suicide attempt following analytically confirmed 25I-NBOMe ingestion. J Psychoactive Drugs 46:379-82
Poklis, Justin L; Clay, Deborah J; Poklis, Alphonse (2014) High-performance liquid chromatography with tandem mass spectrometry for the determination of nine hallucinogenic 25-NBOMe designer drugs in urine specimens. J Anal Toxicol 38:113-21
Lazenka, Matthew F; David, Bethany G; Lichtman, Aron H et al. (2014) Delta FosB and AP-1-mediated transcription modulate cannabinoid CB? receptor signaling and desensitization in striatal and limbic brain regions. Biochem Pharmacol 91:380-9
Sexton, Michelle; Cudaback, Eiron; Abdullah, Rehab A et al. (2014) Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters. Inflammopharmacology 22:295-303